These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 28193650)

  • 1. Interaction of Rifampin and Darunavir-Ritonavir or Darunavir-Cobicistat
    Roberts O; Khoo S; Owen A; Siccardi M
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28193650
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.
    Squillace N; Bozzi G; Colella E; Gori A; Bandera A
    Drug Des Devel Ther; 2018; 12():3635-3643. PubMed ID: 30464395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.
    Putcharoen O; Do T; Avihingsanon A; Ruxrungtham K
    Drug Des Devel Ther; 2015; 9():5763-9. PubMed ID: 26566368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of Antiretroviral Therapy with Boosted Protease Inhibitors-Darunavir/Ritonavir or Darunavir/Cobicistat.
    Marin RC; Behl T; Negrut N; Bungau S
    Biomedicines; 2021 Mar; 9(3):. PubMed ID: 33803812
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of virological response to therapy and resistance profile in treatment-experienced and naive HIV-1 infected Romanian patients receiving regimens containing darunavir boosted with ritonavir or cobicistat.
    Marin RC; Streinu-Cercel A; Moleriu LC; Bungau SG
    Biomed Pharmacother; 2022 Jun; 150():113077. PubMed ID: 35658217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Confirmation of the drug-drug interaction potential between cobicistat-boosted antiretroviral regimens and hormonal contraceptives.
    Majeed SR; West S; Ling KH; Das M; Kearney BP
    Antivir Ther; 2019; 24(8):557-566. PubMed ID: 31933482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Darunavir/cobicistat monotherapy. Experience in a tertiary hospital].
    Yunquera-Romero L; Asensi-Díez R; Del Rio-Valencia JC; Muñoz-Castillo I; Castaño-Carracedo MA
    Rev Esp Quimioter; 2016 Dec; 29(6):308-317. PubMed ID: 27888600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Temsavir, the Active Moiety of the HIV-1 Attachment Inhibitor Prodrug, Fostemsavir, Coadministered with Cobicistat, Etravirine, Darunavir/Cobicistat, or Darunavir/Ritonavir with or without Etravirine in Healthy Participants.
    Moore K; Thakkar N; Magee M; Sevinsky H; Vakkalagadda B; Lubin S; Llamoso C; Ackerman P
    Antimicrob Agents Chemother; 2022 Apr; 66(4):e0225121. PubMed ID: 35315687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Effect of Rifampicin on Darunavir, Ritonavir, and Dolutegravir Exposure within Peripheral Blood Mononuclear Cells: a Dose Escalation Study.
    De Nicolò A; Calcagno A; Motta I; De Vivo E; D'Avolio A; Di Perri G; Wiesner L; Ebrahim IE; Maartens G; Orrell C; McIlleron H
    Antimicrob Agents Chemother; 2022 Jun; 66(6):e0013622. PubMed ID: 35583344
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV treatment simplification to elvitegravir/cobicistat/emtricitabine/tenofovir disproxil fumarate (E/C/F/TDF) plus darunavir: a pharmacokinetic study.
    Harris M; Ganase B; Watson B; Harrigan PR; Montaner JSG; Hull MW
    AIDS Res Ther; 2017 Nov; 14(1):59. PubMed ID: 29096670
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simplification of Antiretroviral Treatment from Darunavir/Ritonavir Monotherapy to Darunavir/Cobicistat Monotherapy: Effectiveness and Safety in Routine Clinical Practice.
    Santos JR; Curran A; Navarro-Mercade J; Ampuero MF; Pelaez P; Pérez-Alvarez N; Clotet B; Paredes R; Moltó J
    AIDS Res Hum Retroviruses; 2019 Jun; 35(6):513-518. PubMed ID: 30909716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immune recovery among Romanian HIV/AIDS patients receiving darunavir/ritonavir or darunavir/cobicistat regimens in cART management: A three-year study.
    Marin RC; Bungau SG; Tit DM; Negru PA; Radu AF; Moleriu RD
    Biomed Pharmacother; 2023 May; 161():114427. PubMed ID: 36822019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of Ethanol on Darunavir Hepatic Clearance and Intracellular PK/PD in HIV-Infected Monocytes, and CYP3A4-Darunavir Interactions Using Inhibition and in Silico Binding Studies.
    Midde NM; Gong Y; Cory TJ; Li J; Meibohm B; Li W; Kumar S
    Pharm Res; 2017 Sep; 34(9):1925-1933. PubMed ID: 28616684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simulation of the impact of rifampicin on darunavir/ritonavir PK and dose adjustment strategies in HIV-infected patients: a population PK approach.
    Dickinson L; Winston A; Boffito M; Khoo S; Back D; Siccardi M
    J Int AIDS Soc; 2014; 17(4 Suppl 3):19586. PubMed ID: 25394092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darunavir/cobicistat showing similar effectiveness as darunavir/ritonavir monotherapy despite lower trough concentrations.
    Gutierrez-Valencia A; Trujillo-Rodriguez M; Fernandez-Magdaleno T; Espinosa N; Viciana P; López-Cortés LF
    J Int AIDS Soc; 2018 Feb; 21(2):. PubMed ID: 29430854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Darunavir/cobicistat maintains the effectiveness of darunavir/ritonavir in HIV-infected patients under mono or dual therapy.
    Mena Á; Cid P; Dueñas C; Garcinuño MÁ; Lorenzo JF; Margusino L; Quiñones M; Grande C; Rodríguez-Osorio I; Castro Á
    HIV Clin Trials; 2018 Oct; 19(5):197-201. PubMed ID: 30605006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous pharmacokinetic modeling of unbound and total darunavir with ritonavir in adolescents: a substudy of the SMILE trial.
    Abdalla S; Compagnucci A; Riault Y; Chan MK; Bamford A; Nolan A; Ramos JT; Constant V; Nguyen T-N; Zheng Y; Tréluyer J-M; Froelicher-Bournaud L; Neveux N; Saidi Y; Cressey TR; Hirt D;
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0100423. PubMed ID: 38092664
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Darunavir concentrations in CSF of HIV-infected individuals when boosted with cobicistat versus ritonavir.
    Bartels H; Decosterd L; Battegay M; Marzolini C
    J Antimicrob Chemother; 2017 Sep; 72(9):2574-2577. PubMed ID: 28575323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drug Interactions with Cobicistat- or Ritonavir-Boosted Elvitegravir.
    Nguyen T; McNicholl I; Custodio JM; Szwarcberg J; Piontkowsky D
    AIDS Rev; 2016; 18(2):101-11. PubMed ID: 27196356
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population Pharmacokinetic Analysis of Darunavir and Tenofovir Alafenamide in HIV-1-Infected Patients on the Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Tablet Regimen (AMBER and EMERALD Studies).
    Ackaert O; McDougall D; Pérez-Ruixo C; Pérez-Ruixo JJ; Jezorwski J; Crauwels HM
    AAPS J; 2021 Jun; 23(4):82. PubMed ID: 34100149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.